Europe
The European Medicines Agency has launched a safety review of bluebird bio’s thalassaemia drug Zynteglo, a conditionally licensed gene therapy in Europe.
This morning, the World Health Organization issued a statement that there is no reason to stop using the vaccine because, as of this time, “no causal link has been established.”
While existing vaccines are being rolled out worldwide, Novavax’s is demonstrating effectiveness in late-stage trials and the partnership of Sanofi and Translate Bio is beginning early-stage trials for their mRNA vaccine.
Patients in a Phase II trial have begun receiving Moderna’s vaccine against the SARS-CoV-2 variant first identified in South Africa, the company announced.
According to the Centers for Disease Control and Prevention, more than 35,000 Americans perish each year from antibiotic-resistant infections, and estimates have AMR claiming the lives of as many as 10 million globally by 2050.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
GlaxoSmithKline failed to hit a key internal profit goal in 2020, due in large part to the impact of the COVID-19 pandemic. As a result, Chief Executive Officer Emma Walmsley took a nearly $2 million hit to her annual compensation.
The drug was being evaluated in 237 adults with locally advanced or metastatic non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and checkpoint inhibitor immunotherapy.
Prescription drug watchdog GoodRx compiled a list of the 10 most expensive drugs on the market. Read further to know more about which drugs are on the list.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
PRESS RELEASES